Diflunisal vs Naproxen — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Nonsteroidal Anti-inflammatory Drug

Diflunisal

Brand: Dolobid

First FDA approval: 2012-03-08

Nonsteroidal Anti-inflammatory Drug

Naproxen

Brand: EC-NAPROXEN

First FDA approval: 2007-04-26

Lowest NADACAcquisition cost floor across all NDCs

$1.19Per unit

$0.046Per unit

Average NADACAcross all dosage forms and strengths

$1.19Up to $1.19

$0.648Up to $8.96

Generic manufacturersActive ANDA holders — FDA Orange Book

35 total ANDAs filed

1750 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$8.0MFull year

$57.0MFull year

Part D claims (CY24)Total fills, all strengths

16K6K beneficiaries

4.4M2.2M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$516Per claim, all NDCs

$13Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes3 manufacturers

Yes17 manufacturers